Roslin Cells recently announced a successful bid to lead a European consortium to establish a major new stem cell bank after winning a three year grant from the Innovative Medicines Initiative.
This consortium will include leading pharmaceutical companies Neusentis/Pfizer, AstraZeneca, H. Lundbeck, Janssen and UCB Pharma, along with several SMEs and academic institutions.
The €35 million project will support the initial build of a robust, reliable supply chain from the generation of customised cell lines, the specification to internationally-accepted quality criteria and their distribution to any global qualified user, ensuring accessibility to consistent, high-quality tools for new medicines development.
Roslin Cells developed new capabilities in induced pluripotent stem (iPS) cells as a result of a Scottish Enterprise (SE) funded project (SIPSS) in collaboration with scientists at the Scottish Centre for Regenerative Medicine at the University of Edinburgh, which has allowed them to play a lead role in this project.
The SIPSS project and further support from SE has helped the company establish itself as a major international player in the iPS and cell therapy fields. Roslin Cells has been selected as the manufacturing partner to support ReNeuron’s ongoing clinical trial for stroke at the Southern General Hospital in Glasgow.
Based within the Edinburgh BioQuarter, and working closely with the Scottish Centre for Regenerative Medicine, Roslin Cells has played a central role in establishing a strong, vibrant stem cell industry in Scotland.
How we support regenerative medicine in Scotland